“Not going to do that”: pessimism about the effectiveness of anti-Govt vaccines against Omigran

“Every scientist I’ve spoken to says, ‘This is not going to happen.’ In an interview Financial Times, The head of Moderna Pharmaceutical Laboratory on Tuesday expressed pessimism about the effectiveness of existing vaccines against the omigran variant of the corona virus.

There will be one “Significant Fall” Efficacy of current vaccines against Omigran, Stephen Bonsell evaluates Due to the lack of accurate data available in the next two weeks, the British newspaper could not calculate it yet.

“I like to think, but I have to be careful, at least part of the vaccine that has been made (…) is likely to protect me to the point where I know nothing.”, For his part, was evaluated at the LCI this Monday by Alain Fischer, chairman of the steering committee for the Covit-19 anti-vaccine strategy.

“Worse or worse, there will be the option of developing new vaccines that no longer use the spike protein of the ‘Wuhan virus’, but replace it with the spike of the Omigron virus.”, Continued believing that “It can go very fast”.

Stephen Bonsell wanted more detail on establishing the large-scale production of this new vaccine. “Several months”.

Various manufacturers, including Moderna, AstraZeneca, Pfizer / BioNTech and Novavax, have announced that they believe in their ability to fight Omicron by developing a new vaccine and will begin to work on this hypothesis. Russia has announced in its “Sputnik V” version that it is specifically targeting Omigron. “Impossible Case” The current serum may not be sufficient. If so, the country will be ready “Deliver hundreds of millions of booster doses to the international market against the Omicron variant by February 20”, Said the Russian Sovereign Fund.

“If it is necessary to replace existing vaccines, we can approve them within three to four months.” Manufacturers from the moment “Begin to change” Emer Cook, director of the European Pharmaceuticals Agency (EMA), told the European Parliamentary Committee. However, he said the decision on whether further injection was necessary should be made by other bodies.

“It’s better to start this process even if you do not need to stop”, On Monday Professor Alain Fischer appraised, recalling that these companies have already gone this route. “For previous delta and gamma types” Most “No need to go too far, much better”.